The Oruka Therapeutics, Inc. (NASDAQ: ORKA) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including current reports, financial statements, and material agreements. As a Nasdaq-listed clinical-stage biotechnology company focused on biologic therapies for chronic skin diseases, Oruka uses its SEC filings to report key corporate, financial, and governance information related to its psoriasis and inflammatory disease programs.
Investors can review Form 8-K current reports where Oruka describes material events such as private placement financings, changes in directors and executive officers, and the terms of securities purchase agreements and registration rights agreements. These filings also document board appointments, committee roles, director compensation, and equity awards, providing detail on corporate governance and leadership transitions.
Periodic reports such as Form 10-Q and Form 10-K (when available) contain condensed consolidated financial statements, including research and development and general and administrative expenses, net losses, cash, cash equivalents, and marketable securities. For a clinical-stage company like Oruka, these filings help readers understand the level of investment in plaque psoriasis and other dermatologic programs, as well as the company’s capital position and runway assumptions.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points, such as trial-related disclosures, financing structures, and changes in share count. Users can also access information related to equity issuances and warrant terms, and track how Oruka’s capital structure evolves over time. Real-time updates from EDGAR ensure that new ORKA filings, including any future proxy statements or insider transaction reports on Form 4, appear promptly with plain-language explanations to support more efficient review.
Oruka Therapeutics, Inc. (ORKA) reported that Chief Commercial Officer Larry Todd Edwards received equity awards on August 24, 2026. He was granted 100,000 shares of Common Stock and an option to purchase 20,000 shares of Common Stock at an exercise price of $102.42 per share, both held directly.
The 100,000-share stock grant vests as to one-quarter on September 14, 2027, with the remaining three-quarters vesting in 12 equal quarterly installments thereafter. The 20,000-share option vests as to one-quarter of the underlying shares on August 24, 2027 and then 1/48 of the underlying shares monthly thereafter, and expires on August 23, 2036. The filing does not indicate use of a Rule 10b5-1 trading plan.
Oruka Therapeutics, Inc. (ORKA) filed an initial statement of beneficial ownership (Form 3) for Larry Todd Edwards, who serves as Chief Commercial Officer. The filing lists him as an officer of the company and does not report any specific equity transactions or detailed holdings in this data.
Oruka Therapeutics, Inc. (ORKA) appointed Todd Edwards as Chief Commercial Officer, effective August 24, 2026, under a July 22, 2026 letter agreement. Edwards is a veteran commercial leader from Arcutis Biotherapeutics, Incyte, UCB, AbbVie and TAP, with extensive experience in dermatology and immunology franchises.
His compensation includes a $525,000 annualized base salary, a discretionary annual bonus targeted at 40% of base salary, a stock option for 20,000 shares and 100,000 RSUs, plus a $200,000 signing bonus. If terminated without cause or he resigns for good reason, he is eligible for 12 months of salary and up to 12 months of company-paid health coverage, with enhanced cash and full equity acceleration upon qualifying terminations around a change in control.
Oruka Therapeutics, Inc. (ORKA) filed a shelf registration to offer and sell up to $1,000,000,000 of common stock, preferred stock, depositary shares and warrants from time to time, with specific terms to be set in future prospectus supplements. Within this, Oruka established a sales agreement with TD Securities (USA) LLC (TD Cowen) allowing an “at the market offering” of up to $500,000,000 of common stock on Nasdaq or other markets, for which TD Cowen may receive up to a 3.0% commission.
As of June 30, 2026, Oruka had 61,069,887 common shares and 137,138 Series B Preferred shares outstanding, out of 545,000,000 authorized common and 5,000,000 authorized preferred. The company reports historical net tangible book value of $1,114.5 million, or $18.25 per share, and illustrates that a hypothetical full use of the ATM at $104.86 per share would increase net tangible book value to $24.29 per share, implying significant dilution to new investors.
Oruka Therapeutics, Inc. executive Joana Goncalves (Chief Medical Officer) reported a series of equity transactions on August 17, 2026. She exercised 3,500 stock options at $6.84 and 3,500 employee warrants at $7.80 to acquire a total of 7,000 shares of common stock, then sold 7,000 shares in multiple open-market transactions at weighted average prices between approximately $109.05 and $112.86. Following these exercises, she held 197,063 options and 168,492 warrants directly. The sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.
Oruka Therapeutics’ General Counsel, Paul T. Quinlan, reported option activity and sales on August 14, 2026. He exercised derivative awards covering 52,000 shares of common stock at exercise prices of $7.80 and $12.50 per share, then sold 52,000 shares of common stock in multiple transactions at weighted-average prices between roughly $105.53 and $111.22. The company confirms these sales were effected under a Rule 10b5-1 trading plan entered into on May 15, 2026. Following the exercises, he reports remaining derivative positions of 89,996 Employee Warrants and 120,500 Employee Stock Options.
Oruka Therapeutics, Inc. Senior Vice President, Finance Arjun Agarwal reported option exercises and share sales in Oruka Therapeutics, Inc. stock. On 2026-08-13 he exercised options for 10,000 shares of common stock (8,542 at $12.50 and 1,458 at $34.39 per share) and on the same date sold 10,000 shares in multiple transactions at weighted average prices between $104.6734 and $108.4628 per share. The sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.
Oruka Therapeutics, Inc. has a large shareholder group led by Venrock Healthcare Capital funds that collectively report beneficial ownership of 4,556,952 shares of common stock, representing 7.4% of the company as of June 30, 2026. These shares are held through Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, L.P., and Venrock Healthcare Capital Partners EG, L.P., together with related management entities and individuals Nimish Shah and Bong Y. Koh.
The ownership includes common stock and Pre-Funded Warrants exercisable for additional shares. The percentage calculation is based on 60,312,101 shares outstanding as of April 30, 2026, plus 800,433 shares issued upon warrant exercises by the reporting persons and 408,524 shares issuable upon exercise of Pre-Funded Warrants. The reporting persons have 0 sole and 4,556,952 shared voting and dispositive power over these shares.
ORKA insider Paul Quinlan filed a Form 144 indicating a proposed sale of common stock. The filing lists up to 71,000 shares of ORKA common stock to be sold through Morgan Stanley Smith Barney LLC on NASDAQ on August 14, 2026, with the shares to be issued from an exercise of stock options for cash. The form also notes a prior sale of 733 shares of common stock during the past three months.